MoonLake Immunotherapeutics (NASDAQ:MLTX) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) in a research report sent to investors on Friday morning,Benzinga reports. The brokerage currently has a $32.00 target price on the stock, up from their previous target price of $26.00.

A number of other equities research analysts have also weighed in on MLTX. Wedbush decreased their price objective on shares of MoonLake Immunotherapeutics from $80.00 to $18.00 and set an “outperform” rating for the company in a report on Tuesday, September 30th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $7.00 target price on shares of MoonLake Immunotherapeutics in a research report on Wednesday, October 1st. BTIG Research upgraded MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and set a $24.00 price target for the company in a report on Friday. Needham & Company LLC dropped their price objective on MoonLake Immunotherapeutics from $66.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, September 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MoonLake Immunotherapeutics in a research report on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $25.54.

MoonLake Immunotherapeutics Price Performance

Shares of MLTX stock opened at $18.49 on Friday. The stock has a 50 day moving average price of $13.18 and a 200 day moving average price of $31.56. The firm has a market capitalization of $1.19 billion, a P/E ratio of -5.57 and a beta of 1.21. The company has a debt-to-equity ratio of 0.25, a quick ratio of 8.50 and a current ratio of 8.50. MoonLake Immunotherapeutics has a 52-week low of $5.95 and a 52-week high of $62.75.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Wednesday, November 5th. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.21). During the same period last year, the firm posted ($0.56) earnings per share. As a group, sell-side analysts predict that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Insider Activity at MoonLake Immunotherapeutics

In related news, CEO Da Silva Jorge Santos sold 130,000 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $15.08, for a total value of $1,960,400.00. Following the completion of the transaction, the chief executive officer owned 2,948,577 shares of the company’s stock, valued at $44,464,541.16. The trade was a 4.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Kristian Reich sold 130,000 shares of the company’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $15.08, for a total value of $1,960,400.00. Following the sale, the insider owned 72,908 shares of the company’s stock, valued at approximately $1,099,452.64. This represents a 64.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 402,908 shares of company stock worth $5,987,162. 12.02% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in MLTX. FNY Investment Advisers LLC purchased a new stake in shares of MoonLake Immunotherapeutics during the third quarter valued at about $28,000. Bank of America Corp DE raised its stake in shares of MoonLake Immunotherapeutics by 64.7% during the 3rd quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after acquiring an additional 1,781 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in MoonLake Immunotherapeutics by 115.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock valued at $42,000 after acquiring an additional 3,166 shares during the last quarter. Covestor Ltd purchased a new stake in MoonLake Immunotherapeutics during the third quarter valued at approximately $46,000. Finally, BNP Paribas Financial Markets boosted its stake in MoonLake Immunotherapeutics by 18.9% in the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock valued at $52,000 after acquiring an additional 1,158 shares in the last quarter. Hedge funds and other institutional investors own 93.85% of the company’s stock.

Key MoonLake Immunotherapeutics News

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: FDA feedback may allow a skin drug filing for SLK without new clinical trials, reducing regulatory risk and supporting a faster BLA path. MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars
• Positive Sentiment: HC Wainwright reaffirmed a Buy and raised its price target to $32, signaling stronger analyst conviction and giving investors a higher upside benchmark. Benzinga: HC Wainwright rating/price target
• Positive Sentiment: Needham maintained a Buy rating and $20 target, citing regulatory de‑risking on HS and 2026 inflammatory disease catalysts as supporting the investment case. MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating
• Positive Sentiment: Retail momentum and speculation about potential M&A conversations amplified the rally, attracting heavy trading volume and short‑term buying interest. MLTX stock extends rally as FDA feedback spurs bullish brokerage action – retail speculates on potential M&A conversations
• Neutral Sentiment: Analysts and commentators view the FDA Type B meeting as momentum ahead of a planned BLA submission; this is positive if regulators agree but not a guarantee of approval. MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission
• Neutral Sentiment: Explanatory pieces trace the pre‑market surge and investor interest — useful for context but not new catalyst information. Why MoonLake Immunotherapeutics’s (MLTX) Stock Is Up 34.28%
• Negative Sentiment: Fundamentals remain loss‑making (recent EPS misses and negative forecasted EPS), and regulatory outcomes or labeling negotiations could still require additional data or post‑market commitments. Investors should weigh binary regulatory risk and past volatility. MarketBeat MLTX profile (financials & recent results)

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.